UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 261

Sortiert nach

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma

Proceedings of the National Academy of Sciences - PNAS, 2019-02, Vol.116 (6), p.2210-2219

2019

Volltextzugriff (PDF)

Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients

Clinical cancer research, 2012-12, Vol.18 (23), p.6497-6508

2012

Volltextzugriff (PDF)

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies

Scientific reports, 2021-02, Vol.11 (1), p.3718-3718, Article 3718

2021

Volltextzugriff (PDF)

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2010-01, Vol.28 (2), p.207-214

2010

Volltextzugriff (PDF)

Time to publication of oncology trials and why some trials are never published

PloS one, 2017-09, Vol.12 (9), p.e0184025-e0184025

2017

Volltextzugriff (PDF)

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

Modern pathology, 2010-08, Vol.23 (8), p.1104-1112

2010

Volltextzugriff (PDF)

Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion

PloS one, 2015-05, Vol.10 (5), p.e0126633

2015

Volltextzugriff (PDF)

The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells

Cancers, 2019-10, Vol.11 (11), p.1678

2019

Volltextzugriff (PDF)

Galectins and Ovarian Cancer

Cancers, 2020-05, Vol.12 (6), p.1421

2020

Volltextzugriff (PDF)

Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

Journal of clinical oncology, 2002-06, Vol.20 (12), p.2824-2831

2002

Volltextzugriff (PDF)

Structural basis for antibody recognition of the proximal MUC16 ectodomain

Journal of ovarian research, 2024-02, Vol.17 (1), p.41-41, Article 41

2024

Volltextzugriff (PDF)

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

Clinical cancer research, 2010-01, Vol.16 (1), p.358-366

2010

Volltextzugriff (PDF)

Ovarian Cancer Treatment — Are We Getting Warmer?

The New England journal of medicine, 2018-01, Vol.378 (3), p.293-294

2018

Volltextzugriff (PDF)

Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth

ACS chemical biology, 2017-08, Vol.12 (8), p.2085-2096

2017

Volltextzugriff (PDF)

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer

Journal of translational medicine, 2015-03, Vol.13 (1), Article 102

2015

Volltextzugriff (PDF)

Nomogram to Predict Cycle-One Serious Drug-Related Toxicity in Phase I Oncology Trials

Journal of clinical oncology, 2014-02, Vol.32 (6), p.519-526

2014

Volltextzugriff (PDF)

Sialyl-Tn serves as a potential therapeutic target for ovarian cancer

Journal of ovarian research, 2024-04, Vol.17 (1), p.71-16, Article 71

2024

Volltextzugriff (PDF)

A Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies

Clinical cancer research, 2002-08, Vol.8 (8), p.2505-2511

2002

Volltextzugriff (PDF)

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer

Journal of translational medicine, 2015-03, Vol.13, p.102-102

2015

Volltextzugriff (PDF)

A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies

Clinical trials (London, England), 2008-10, Vol.5 (5), p.465-477

2008

Volltextzugriff (PDF)

Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Clinical cancer research, 2007-07, Vol.13 (14), p.4170-4177

2007

Volltextzugriff (PDF)

Beyond the dose‐limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program

Cancer, 2016-04, Vol.122 (8), p.1228-1237

2016

Volltextzugriff (PDF)

Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission

Clinical cancer research, 2008-05, Vol.14 (9), p.2740-2748

2008

Volltextzugriff (PDF)

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Cancers, 2016-04, Vol.8 (4), p.46

2016

Volltextzugriff (PDF)

Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer

Journal of clinical oncology, 2011-12, Vol.29 (35), p.4662-4668

2011

Volltextzugriff (PDF)

1 – 25 von 261

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(251)
Mit Volltextzugriff
(236)

Publikationsform

Sprache

Englisch
(261)
Japanisch
(35)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(38)
Gynecologic Oncology
(25)
Cancer Research
(24)
Clinical Cancer Research
(16)
The New England Journal Of Medicine
(12)
Cancer
(10)
Investigational New Drugs
(7)
Nature
(7)
Blood
(5)
Cancer Chemotherapy And Pharmacology
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma

Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors

Time to publication of oncology trials and why some trials are never published

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion

The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells

Galectins and Ovarian Cancer

Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

Structural basis for antibody recognition of the proximal MUC16 ectodomain

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

Ovarian Cancer Treatment — Are We Getting Warmer?

Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer

Nomogram to Predict Cycle-One Serious Drug-Related Toxicity in Phase I Oncology Trials

Sialyl-Tn serves as a potential therapeutic target for ovarian cancer

A Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer

A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies

Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Beyond the dose‐limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program

Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer

Suchergebnisse filtern